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We read with great interest the manuscript by Yang et al. (Yang et al., 2015) , which was published in a recent issue of the journal. The authors report the utility and advantages of an elegant PBPK model, compared with a traditional AUC approach, for the estimation of the fraction of hepatic clearance of verapamil (VER) that forms norverapamil (NOR) (݄ ா ோ ՜ ே ை ோ ) in an isolated perfused rat liver (IPRL) preparation. The authors graciously cite several of our prior works with verapamil in interpreting their data (Mehvar et al., 1994; Mehvar and Reynolds, 1995; Mehvar and Reynolds, 1996; Robinson and Mehvar, 1996) . In particular, they cite, on multiple instances, our study on the hepatic disposition of VER and its VER-generated and preformed N-demethylated metabolite (NOR) enantiomers in an IPRL model (Mehvar et al., 1994) . Unfortunately, it appears that the authors have misinterpreted and/or inaccurately cited our published data in several places in their article. In particular, they compare
estimated in their study with a similar parameter obtained in our report. They mistakenly state that our
value is 0.12, compared with their value of 0.31, and inaccurately attribute this difference to our "failure to account for sequential metabolism ( ‫ܨ‬ ே ை ோ ), the attendant nonlinearity in metabolism, and binding to red blood cells." Additionally, they unfortunately misquote several other kinetic parameters from our study such as our free fractions of the VER enantiomers in a bovine serum albumin solution and VER hepatic intrinsic clearance, among others. These issues are clarified and addressed in more detail in the following paragraphs.
First, it is puzzling why or how the authors could have quoted a value of 0.12 for
from our study. In our report (Mehvar et al., 1994) , we estimated the fraction of the extracted VER enantiomers converted to NOR at steady state, a parameter that should be similar Table 2 in (Yang et al., 2015) ].
Additionally, our values of 0.23 and 0.19 are much closer than the misquoted value of 0.12 to their value of 0.31, which was obtained from their fitting the data to a PBPK model.
Second, the authors attribute the inaccurately quoted much lower value of
(0.12) to our failure to recognize sequential metabolism, nonlinearity in the metabolism of verapamil, and the binding to red blood cells, which is not an accurate interpretation of our data.
In our article, we used the following equation [equation (5) in (Mehvar et al., 1994) ] to estimate the fraction of infused VER enantiomer converted into its respective enantiomer of NOR during one passage through the liver at steady-state (F m ):
where recirculating system used by Yang et al. (Yang et al., 2015) , which mimics intravenous dosing, thus the additional requirement for correction by ‫ܨ‬ ே ை ோ in their study. It would appear that the source of misinterpretation of our data is most likely the failure of Yang et al. (Yang et al., 2015) to recognize the differences between the addition of VER or NOR to their perfusate in their recirculating system (i.e., similar to intravenous dosing) and administration of VER or NOR into the portal inlet (i.e., similar to oral dosing) in our single-pass model. Nevertheless, these calculations assume that the metabolism of VER-generated NOR and the preformed NOR, administered as such, are similar. Additionally, these calculations assume linear pharmacokinetics. Our inlet concentrations of VER enantiomers were ~1.2 µM, which were within two-fold of the lowest racemic concentration of 1 µM used by Yang et al. (Yang et al., 2015) and far from their high saturating concentrations of 50 and 100 µM. Nevertheless, we 
The above equation is simplified to the following equation:
This article has not been copyedited and formatted. The final version may differ from this version. ratio. However, we used only a 10% red blood cell in our study (Mehvar et al., 1994) , and the (Mehvar and Reynolds, 1996) . Therefore, in contrast to the suggestion by Yang et al. (Yang et al., 2015) , a lack of consideration of the red blood cell uptake in our studies is unlikely to have affected the differences, if any, between our F m values and their
Lastly, the authors inaccurately cite a number of parameters from our study. For example, they state that our unbound fractions of R-VER and S-VER in a 2% bovine serum albumin were ~0.65 and ~0.55, respectively. However, as our data ( Fig. 3 in (Mehvar et al., 1994) ] clearly show, we reported free fractions of 0.23 and 0.12, respectively. Furthermore, they cite a value of 50-130 ml/min from our study for total hepatic intrinsic clearance of VER ‫ܮܥ(‬ ௧ , ௧ ௧ ா ோ ), whereas in reality our values were 260 and 430 ml/min (Table I, in (Mehvar et al., 1994) ].
In conclusion, the fractions of VER converted to its metabolite NOR in our single-pass IPRL (0.23 and 0.19 for the S-and R-enantiomers, respectively) are in complete agreement with the value reported by Yang et al. when a similar method, based on the AUCs of VER and generated and preformed NOR, was used to estimate this parameter in a recirculating IPRL after a relatively low dose of VER. However, when the authors used the maximum velocity and Michaelis-Menten parameters of VER and NOR metabolism in a PBPK model to estimate this parameter, a higher value (0.31) was obtained (Yang et al., 2015) . Tables 2 and   5 in (Yang et al., 2015) ], it is hard to argue for a marked difference between the traditional AUC method at a low VER dose and the PBPK model for the estimation of this parameter.
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